FundedIQ
Biotechnology

Cresilon, Inc.: Funding, Investors & Team (Sep 2026)

Cresilon is a medical device company that produces and markets solutions for trauma care. The company’s proprietary product, VETIGEL(TM), is a hemostatic gel made from plant-derived materials to stop traumatic bleeding in seconds. It functions as a blood-clotting agent, and also as a scaffold to facilitate skin growth. Cresilon was co-founded by Joe Landolina and Isaac Miller in 2010 and is based in New York, United States.

www.cresilon.com LinkedIn Brooklyn, United States 11-50 employees
Biotechnology Health Care Medical Medical Device
Total raised
$31.0M
Rounds
2
Latest
Undisclosed round
Sep 2025

Cresilon, Inc. has raised $31.0M across 2 funding rounds on record, the most recent an undisclosed round of $17.0M announced in Sep 2025.

That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.

Cresilon, Inc. Company Profile and Key Stats

Total funding raised
$31.0M
across 2 rounds on record
Funding rounds on record
2
Latest funding round
Undisclosed round
$17.0M in Sep 2025
Employees
11-50
reported band
Headquarters
Brooklyn, United States

Latest funding round on record: Sep 2025.

Cresilon, Inc. Funding Rounds

Date
Round
Amount
Undisclosed round
$17.0M
Series A
$14.0M

Cresilon, Inc. raised $14.0M in a Series A announced in Apr 2021.

4.4 years later, an undisclosed round of $17.0M was announced in Sep 2025.

Cresilon, Inc. Founders and Leadership Team

Name
Role
Contact
Joe Landolina
CEO

No contact details are on record for this team yet.

Cresilon, Inc. Funding Compared to Other Biotechnology Startups

Segment
Companies
Median round
4,183
$8.0M
29,878
$7.5M

Cresilon, Inc.'s latest round of $17.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.

Funded Startups Like Cresilon, Inc. in Biotechnology and Brooklyn

Companies Similar to Cresilon, Inc.

SeqWell’s is a biotechnology company that specializes in the fields of gene sequencing and laboratory…

Undisclosed round $960k

DermaSensor’s mission is to save lives and healthcare costs by providing easy access to effective skin cancer…

Series B $4.0M

Solstice Oncology is a clinical stage immuno-oncology company

Series A $225M

Encoded Therapeutics is a developer of precision gene therapies intended to provide treatment for a broad…

Series F $275M

BrainChild Bio is a biotechnology company in the clinical stage that specializes in pediatric brain tumors.…

Series A $116M

Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…

Series B $65.5M

Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…

Seed $7.0M

ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…

Series C $10.0M

EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…

Series A $35.0M

Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…

Convertible Note $3.5M

Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…

Convertible Note $6.8M

XiltriX North America is an information technology company that specializes in monitoring, predictive…

Undisclosed round $3.0M

Cresilon, Inc. Funding FAQs

What does Cresilon, Inc. do?

Cresilon is a medical device company that produces and markets solutions for trauma care. The company’s proprietary product, VETIGEL(TM), is a hemostatic gel made from plant-derived materials to stop traumatic bleeding in seconds. It functions as a blood-clotting agent, and also as a scaffold to facilitate skin growth. Cresilon was co-founded by Joe Landolina and Isaac Miller in 2010 and is based in New York, United States.

How much funding has Cresilon, Inc. raised?

Cresilon, Inc. has raised $31.0M across 2 rounds on record. The most recent is an undisclosed round of $17.0M announced in Sep 2025.

When did Cresilon, Inc. last raise funding?

Cresilon, Inc.'s most recent funding round on record is an undisclosed round of $17.0M, announced in Sep 2025.

Who is the CEO of Cresilon, Inc.?

Joe Landolina is listed as CEO at Cresilon, Inc..

Where is Cresilon, Inc. headquartered?

Cresilon, Inc. is based in Brooklyn, New York, United States.

How many employees does Cresilon, Inc. have?

Cresilon, Inc. is in the 11-50 employee band.

How does Cresilon, Inc.'s funding compare to other Biotechnology startups?

Cresilon, Inc.'s latest round of $17.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,183 tracked companies over the last two years.

About FundedIQ's Cresilon, Inc. Funding Data

FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.

Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Cresilon, Inc. is left off this page rather than filled in.

14-day free trial · Cancel anytime

Know who just raised. Then know who to reach.

Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.

Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.